STOCK TITAN

Oncternal Therapeutics Inc - ONCT STOCK NEWS

Welcome to our dedicated news page for Oncternal Therapeutics (Ticker: ONCT), a resource for investors and traders seeking the latest updates and insights on Oncternal Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncternal Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncternal Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.84%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.48%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.64%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.59%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.61%
Tags
conferences
Oncternal Therapeutics Inc

Nasdaq:ONCT

ONCT Rankings

ONCT Stock Data

27.82M
2.65M
8.75%
16.13%
0.57%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About ONCT

oncternal therapeutics, inc., a clinical-stage biopharmaceutical company, develops oncology therapies for the treatment of cancers with critical unmet medical need. the company's product pipeline include cirmtuzumab, a monoclonal antibody designed to inhibit the receptor-tyrosine kinase-like orphan receptor 1 (ror1) that is in phase i/ii clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma and chronic lymphocytic leukemia; and is in phase ib clinical trial in combination with paclitaxel for the treatment of women with human epidermal growth factor receptor 2-negative metastatic or breast cancer. it also develops tk-216, a small-molecule that is designed to inhibit e26 transformation specific family of oncoproteins, which is in phase i clinical trial to treat patients with ewing sarcoma and in combination with vincristine chemotherapy. in addition, the company develops a chimeric antigen receptor-t product candidate that targets ror1, whic